Cargando…

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors. Normal pituitary tissue expresses somatostatin receptors so patients receiving PRRT may be at risk of developing hypopituitarism. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elston, Marianne S., Love, Amanda, Kevat, Dev, Carroll, Richard, Siow, Zhen Rong, Pattison, Sharon, Boyle, Veronica, Segelov, Eva, Strickland, Andrew H., Wyld, David, Gauci, Richard, Kennedy, Kim, Ransom, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633256/ https://www.ncbi.nlm.nih.gov/pubmed/34697905 http://dx.doi.org/10.1002/cam4.4345

Ejemplares similares

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
por: Lim, Lisi Elizabeth, et al.
Publicado: (2020)

Risk of Lung Cancer Mortality in Nuclear Workers from Internal Exposure to Alpha Particle-emitting Radionuclides
por: Grellier, James, et al.
Publicado: (2017)

Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care
por: Woodhouse, Braden, et al.
Publicado: (2019)

Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)

Giant Pituitary Adenoma Presenting With Disinhibition: A Case Report of a 25-Year-Old Male
por: Nottingham, Saleen, et al.
Publicado: (2021)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
por: Yordanova, Anna, et al.
Publicado: (2020)

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
por: Volpe, Alessia, et al.
Publicado: (2018)

The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis
por: Guccione, Lisa, et al.
Publicado: (2023)

The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary
por: Marques, Pedro
Publicado: (2023)

Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI
por: Arnfield, Evyn G., et al.
Publicado: (2023)

Pituitary Apoplexy in Patients with Pituitary Neuroendocrine Tumors (PitNET)
por: Gheorghe, Ana-Maria, et al.
Publicado: (2023)

Body Image Disturbance in Acromegaly Patients Compared to Nonfunctioning Pituitary Adenoma Patients and Controls
por: Conaglen, Helen M., et al.
Publicado: (2015)

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
por: Wong, Chung, et al.
Publicado: (2012)

Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine‐non‐neuroendocrine neoplasm
por: Zhang, Panpan, et al.
Publicado: (2021)

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
por: Giuffrida, G, et al.
Publicado: (2019)

Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma
por: Lin, Andrew L, et al.
Publicado: (2021)

Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
por: Taboada, Rodrigo G, et al.
Publicado: (2022)

Pituitary Neuroendocrine Tumor: Is It Benign or Malignant?
por: Lee, Chae Heuck
Publicado: (2023)

Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up
por: Duan, Heying, et al.
Publicado: (2022)

Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer
por: Yan, Peng, et al.
Publicado: (2021)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
por: Asbach, Stefan, et al.
Publicado: (2017)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
por: Starr, Jason S, et al.
Publicado: (2020)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells
por: Oh, Jun Y., et al.
Publicado: (2022)

PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
por: Cossu, Giulia, et al.
Publicado: (2023)

Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
por: Kipnis, Sarit T., et al.
Publicado: (2021)

Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
por: Marques, Pedro, et al.
Publicado: (2019)

Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors
por: Ter‐Minassian, Monica, et al.
Publicado: (2017)

Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years
por: Al Subhi, Abdul Rahman, et al.
Publicado: (2022)

SAT440 DRESS/DHIS-associated Thyroiditis And Hypophysitis
por: Ranasinghe, Indika R, et al.
Publicado: (2023)

Pituitary adenoma or pituitary neuroendocrine tumor: a narrative review of controversy and perspective
por: Liu, Xiaohai, et al.
Publicado: (2021)

Biomarkers for Liquid Biopsies of Pituitary Neuroendocrine Tumors
por: Gossing, Wilhelm, et al.
Publicado: (2020)

Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy
por: Zhou, Yuhang, et al.
Publicado: (2023)

Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study
por: Zhou, Huaqiang, et al.
Publicado: (2017)

The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors
por: Phan, Alexandria T., et al.
Publicado: (2016)

A Comparative Study of Neuroendocrine Heterogeneity in Small Cell Lung Cancer and Neuroblastoma
por: Cai, Ling, et al.
Publicado: (2023)

Targeted Radionuclide Therapy
por: Ersahin, Devrim, et al.
Publicado: (2011)

SUN-914 Peptide Receptor Radionuclide Therapy for an Inoperable Small Cell Neuroendocrine Tumor in the Philippines
por: Alegria, Rainier Mark Gabriel
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l4ogo20c1tnvqpnsaomiipvp3k